|1.||Holst, Jens J: 26 articles (10/2015 - 01/2002)|
|2.||Holst, J J: 24 articles (10/2012 - 05/2000)|
|3.||Vilsbøll, Tina: 21 articles (10/2015 - 11/2004)|
|4.||Knop, Filip K: 15 articles (10/2015 - 08/2007)|
|5.||Nauck, Michael A: 12 articles (08/2015 - 03/2004)|
|6.||Deacon, Carolyn F: 12 articles (04/2015 - 03/2004)|
|7.||Horowitz, Michael: 11 articles (12/2015 - 05/2006)|
|8.||Drucker, Daniel J: 11 articles (05/2014 - 01/2002)|
|9.||Holst, Jens Juul: 10 articles (08/2015 - 12/2006)|
|10.||Madsbad, Sten: 10 articles (05/2015 - 12/2006)|
|1.||Weight Loss (Weight Reduction)
12/01/2014 - "Incretin based therapy was found to improve B cell mass and glycaemic control in addition to having multiple beneficial effects on the systolic and diastolic blood pressure, weight loss in addition to their other beneficial effects on the liver and cardiovascular system. "
01/01/2014 - "The combination of an SGLT2 inhibitor and an incretin mimetic/analog results in improved glycemic control accompanied by significant weight loss. "
04/01/2008 - "Only incretin-mimetics have a lowering HbA1c action, due to the improvement in beta-cell function, which is coupled to significant weight loss. "
03/01/2010 - "In contrast, the blunted incretin effect (calculated at 22%) that improved at 1 month remained unchanged with further weight loss at 6 (52%) and 12 (52%) months. "
02/01/2006 - "The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. "
|2.||Hypoglycemia (Reactive Hypoglycemia)
01/01/2011 - "Modulators of incretin physiology have been shown to improve glycemic control with a low risk for hypoglycemia and beneficially affect β-cell function. "
01/01/2015 - "Incretin-based therapy has clearly emerged as one of the most sought out strategy in managing type 2 diabetes, primarily because they generally do not causes hypoglycemia and possess weight-neutral or weight losing properties. "
12/01/2013 - "Newer therapies (like incretin-based therapies) are instead associated with a very low hypoglycemia risk. "
12/01/2013 - "In addition, several characteristics of incretin therapies may improve rates of medication adherence, such as generally favorable tolerability profiles (particularly with DPP-4 inhibitors), the availability of formulations that simplify treatment regimens, and a low risk for hypoglycemia. "
07/01/2013 - "Incretin-based therapies are characterized by an overall favorable safety profile and weight effect, a low risk of hypoglycemia, and clinically meaningful improvements in HbA1c. "
|3.||Type 2 Diabetes Mellitus (MODY)
05/01/2014 - "Incretin-based therapies have been shown to be effective across the spectrum of type 2 diabetes mellitus, including recent-onset diabetes. "
01/01/2013 - "The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus. "
01/01/2012 - "In recent years the incretin therapies have provided a new treatment option for patients with type 2 diabetes mellitus (T2DM). "
10/01/2012 - "The aim of this study was to evaluate the beta cell and incretin function in patients with HNF4A and HNF1A MODY during a test meal. "
10/01/2012 - "Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus."
11/01/2008 - "Inhibition of this enzyme results in an increase in the half-life and the sustained physiologic action of incretins, leading to an improvement in hyperglycemia. "
10/01/2015 - "This profile has been attributed to effects of relative hyperglycemia to directly stimulate β-cells and an augmented incretin effect. "
07/01/2015 - "This review details the specific mechanistic value of incretins in patients with immunosuppression-associated hyperglycemia. "
09/01/2014 - "Use of incretin-based therapy in hospitalized patients with hyperglycemia."
03/01/2014 - "Incretin-based therapies are now well established for diabetes management and are among the frontline agents for control of hyperglycemia. "
05/01/2012 - "Insulin resistance and IGT, representing two stages in the path towards diabetes, are associated with differential reductions in the incretin effect seen before the development of IGT and overt type 2 diabetes. "
01/01/2012 - "While the current management approach for T2DM continues to encompass traditional drugs that focus on β-cell failure and/or insulin resistance, newer agents that target other defects (eg, incretin deficiency/resistance) are increasingly incorporated. "
10/01/2011 - "The G allele was also independently associated with insulin resistance, impaired pancreatic β cell function, and incretin effect during the OGTT. "
04/01/2011 - "Decreased incretin secretion seems to develop early in the course of type 2 diabetes with increasing insulin resistance, but not to be influenced by glycaemic status."
09/01/2010 - "We also discuss therapeutic potentialities of incretin-based therapies, new anti-diabetic agents for HCV-associated insulin resistance and the significance of insulin resistance in the era of new anti-viral treatments."
|3.||Glucagon-Like Peptide 1 (GLP 1)
|6.||glucagon-like peptide receptor (receptor, glucagon-like peptide)
|2.||Gastric Bypass (Roux-en-Y Gastric Bypass)